Clinical Outcome and Diverse Risk Factors for Different Therapeutic Target Locations of Peripheral Artery Disease.

CONCLUSIONS: In patients with PAD, OS was largely defined by comorbidities but not by lesion location. The background risk factors, underlying comorbidities, and event rates were different according to PAD location, suggesting that stratified treatment should be established for different patient populations. PMID: 31723087 [PubMed - as supplied by publisher]
Source: Journal of Atherosclerosis and Thrombosis - Category: Cardiology Tags: J Atheroscler Thromb Source Type: research

Related Links:

CONCLUSIONS: The current study analyzed nationwide procedural databases and demonstrated the presentation pattern of symptomatic PAD and CAD warranting revascularization. PMID: 31748468 [PubMed - as supplied by publisher]
Source: Journal of Atherosclerosis and Thrombosis - Category: Cardiology Tags: J Atheroscler Thromb Source Type: research
Abstract Macrophages play a central role in the development of atherosclerotic cardiovascular disease (ASCVD), which encompasses coronary artery disease, peripheral artery disease, cerebrovascular disease, and aortic atherosclerosis. In each vascular bed, macrophages contribute to the maintenance of the local inflammatory response, propagate plaque development, and promote thrombosis. These central roles, coupled with their plasticity, makes macrophages attractive therapeutic targets in stemming the development of and stabilizing existing atherosclerosis. In the context of ASCVD, classically activated M1 macrophag...
Source: Arteriosclerosis, Thrombosis and Vascular Biology - Category: Cardiology Authors: Tags: Arterioscler Thromb Vasc Biol Source Type: research
This review provides the rationale for dual pathway inhibition with the combination of low-dose rivaroxaban (2.5  mg twice daily) to attenuate thrombin generation and aspirin (100 mg once daily) to reduce platelet activation. Such therapy has been licensed for secondary prevention in patients with coronary or peripheral artery disease.
Source: Thrombosis Research - Category: Hematology Authors: Tags: Review Article Source Type: research
CONCLUSIONSː NOACs reduced all-cause mortality in patients with or at risk for CAD or PAD, even though they increased the risk of major bleeding. Future studies regarding the best doses of NOACs are warranted. PMID: 31625706 [PubMed - as supplied by publisher]
Source: Minerva Cardioangiologica - Category: Cardiology Tags: Minerva Cardioangiol Source Type: research
Sky Medical Technology Ltd. won FDA clearance for a device that stimulates calf muscles to prevent venous thrombosis in non-surgical patients at risk for venous thromboembolism. The Daresbury, England-based company said the geko device is the first muscle pump activator of its kind to be cleared by FDA for VTE prevention across all patients. Sky Medical Technology’s geko is a non-invasive battery-powered, wearable therapy device that is about the size of wristwatch. The technology is worn at the knee. Geko works by gently stimulating the common peroneal nerve, activating the calf and foot muscle pumps, re...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news
CONCLUSION: Institutional volume was associated with the 12-month restenosis rate after AI stenting for PAD, although comparable perioperative outcomes were also observed between high-volume and low-volume hospitals. PMID: 31588072 [PubMed - as supplied by publisher]
Source: Journal of Atherosclerosis and Thrombosis - Category: Cardiology Tags: J Atheroscler Thromb Source Type: research
ology; Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; and Council on Cardiovascular Surgery and Anesthesia Abstract Pulmonary embolism (PE) represents the third leading cause of cardiovascular mortality. The technological landscape for management of acute intermediate- and high-risk PE is rapidly evolving. Two interventional devices using pharmacomechanical means to recanalize the pulmonary arteries have recently been cleared by the US Food and Drug Administration for marketing, and several others are in various stages of development. The purpose of this document is to clarify the curr...
Source: Circulation - Category: Cardiology Authors: Tags: Circulation Source Type: research
The M&A’s just keep coming this week as AngioDynamics announced a plan acquire Eximo Medical. Latham, NY-based AngioDynamics will pick up the company for about $46 million in up-front consideration with the possibility of up to $20 million in milestones. The announcement comes a day after Lantheus Holdings revealed its intention to acquire Progenics Pharmaceuticals. Eximo has developed technology that delivers short, high-powered pulsed-laser energy in 355nm wavelength without compromising the integrity of its fiber optic cables during atherectomy procedures. The technology addresses the risk of perforati...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Cardiovascular Source Type: news
ConclusionMS patients in the UK and the US have increased risk of venous thromboembolism and peripheral vascular disease. The risk of myocardial infarction is increased among female MS patients.
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
We report a case of a female patient with rapidly advancing blue discoloration of her feet. Peripheral artery disease (PAD) and thrombosis were quickly ruled out. Eventually, she required transmetatarsal amputation for gangrene. Pathologic analysis confirmed the unexpected diagnosis of fibromuscular dysplasia (FMD), an arterial disease that most frequently causes renal and carotid artery stenosis. Common symptoms include secondary hypertension refractory to antihypertensives, dizziness and pulsatile tinnitus, and abdominal pain due to mesenteric artery involvement.
Source: Mayo Clinic Proceedings - Category: Internal Medicine Authors: Tags: Letter to the editor Source Type: research
More News: Cardiology | Dialysis | Peripheral Vascular Disease (PVD) | Statistics | Study | Thrombosis